GoodRx appoints Laura Jensen as chief commercial officer

SANTA MONICA - GoodRx (NASDAQ:GDRX), a medication savings platform in the U.S. with a market capitalization of $1.9 billion and impressive gross profit margins of 93.84%, announced Monday the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions, effective July 28, 2025. According to InvestingPro data, the company maintains a "GREAT" financial health score.

Jensen joins GoodRx from Amazon Pharmacy, where she served as Head of Manufacturer & Prescriber Business Development. In her previous role, she led strategic partnerships connecting prescribers and pharmacy workflows across Amazon Pharmacy and PillPack.

At GoodRx, Jensen will lead the company’s Pharma Manufacturer Solutions offering and oversee strategic initiatives aimed at enhancing partnerships across the pharmaceutical industry.

"I’m thrilled to join the GoodRx team that has built the most trusted and widely used medication savings platform by consumers and healthcare professionals in the country," Jensen said in a statement.

Prior to Amazon Pharmacy, Jensen held positions at pharmaceutical companies including UCB and GlaxoSmithKline, where she led initiatives in sales, marketing, operations, and commercial innovation.

GoodRx CEO Wendy Barnes expressed confidence that Jensen’s experience across pharmaceutical, consumer health, and pharmacy ecosystems would help deepen the company’s impact and accelerate growth.

According to the press release, GoodRx’s platform is used by nearly 30 million consumers and over one million healthcare professionals annually. The company reports having helped Americans save over $85 billion on medication costs since its founding in 2011. With the company’s next earnings report due on August 6, investors can access comprehensive analysis and valuation metrics through the detailed Pro Research Report available on InvestingPro.

In other recent news, GoodRx Holdings Inc. reported its Q1 2025 earnings, which met earnings per share (EPS) expectations and slightly exceeded revenue forecasts. The company achieved an EPS of $0.09, aligning with projections, and reported revenue of $202.97 million, surpassing the anticipated $202.59 million. This modest revenue beat, along with strong adjusted EBITDA growth, contributed to positive market sentiment. Furthermore, KeyBanc Capital Markets maintained its Overweight rating on GoodRx, with a price target of $6.00. Analyst Scott Schoenhaus commented on the company’s strategic efforts to navigate challenges in the retail pharmacy industry, such as the RiteAid bankruptcy. GoodRx’s management is focusing on initiatives to stabilize and grow revenue, including direct contracting strategies. These efforts are expected to enhance margins by involving manufacturers, retailers, pharmacy benefit managers, and consumers. While a re-acceleration of Monthly Active Consumers might be delayed until next year, the company’s strategic moves are anticipated to provide long-term benefits.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.